Silo Pharma Inc. (NASDAQ: SILO) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering its lead intranasal therapeutic, SPC-15, aimed at treating post-traumatic stress disorder (PTSD). The invention, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior,” encompasses both composition and method claims for the company's proprietary approach to preventing or delaying stress-induced behavioral responses. This allowance follows a corresponding patent issued by the Japan Patent Office earlier this year, signaling expanding global protection for the technology.
A Notice of Allowance means the USPTO has completed its examination and determined that the application meets all requirements for patentability, and the patent is expected to be granted shortly. For Silo Pharma, this development is critical as it advances SPC-15 through the development pipeline. Patent protection provides a competitive barrier, potentially securing market exclusivity and attracting investment necessary for costly clinical trials. The U.S. patent adds to Silo’s growing biopharmaceutical intellectual property portfolio, which already includes issued and allowed patents. According to the company, this protection is an important component of its strategy as it pursues SPC-15 for PTSD.
PTSD affects millions of people worldwide, and existing treatments often have limited efficacy or tolerability. SPC-15’s intranasal delivery could offer a more convenient and rapid-acting option, addressing a significant unmet need. The patent allowance not only validates the novelty of Silo’s approach but also enhances the company’s position in the competitive CNS space. For investors, this milestone reduces regulatory risk and underscores Silo’s commitment to developing innovative therapies for underserved conditions.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus includes stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Beyond SPC-15, the portfolio features SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Research is conducted in collaboration with leading universities and laboratories, which may further bolster the scientific foundation of these programs.
The full press release can be viewed at https://ibn.fm/Hh4Z6. For ongoing updates, the company’s newsroom is available at https://ibn.fm/SILO.
This patent allowance comes at a time when mental health innovation is increasingly prioritized by regulators and payers. If SPC-15 succeeds in clinical trials, it could become a first-in-class treatment, potentially capturing a substantial share of the PTSD market. The strategic value of strong IP protection cannot be overstated, as it may facilitate partnerships or licensing deals. Silo’s dual focus on biopharma and cryptocurrency treasury adds an unconventional dimension, but the core value driver remains its therapeutic pipeline. With the U.S. patent on the horizon, Silo Pharma is better positioned to advance SPC-15 and attract the resources needed to bring this therapy to patients.
